Cancer Screening
Breast Cancer CA 15-3 Rapid Test Kits
breastCancer.png

Early diagnosis IS KEY

 

BACKGROUND

Latest global cancer data

icon_check_edited.png
icon_g_one5.png

One in 5 people develop cancer during their lifetime

icon_g_one8.png

One in 8 men die from the cancer

icon_g_one11.png

One in 11 women die from the cancer

The global cancer burden is estimated to have risen to 19.3 million new cases and 10.0 million deaths in 2020.1 One in 5 people worldwide develop cancer during their lifetime, and one in 8 men and one in 11 women die from the disease.

Latest global cancer data

icon_check_edited.png

Major cancer types in 2020

The 10 most common cancer types account for more than 60% of the newly diagnosed cancer cases and more than 70% of the cancer deaths. Female breast cancer is the most commonly occurring cancer worldwide (11.7% of the total new cases), followed by lung cancer (11.4%), colorectal cancer (10.0%), prostate cancer (7.3%), and stomach cancer (5.6%).

In men, lung cancer is the most commonly diagnosed cancer and the leading cause of cancer death, followed by prostate cancer and colorectal cancer for incidence and liver cancer and colorectal cancer for mortality.

In women, breast cancer is the most commonly diagnosed cancer and the leading cause of cancer death, followed by colorectal cancer and lung cancer for incidence and lung cancer and colorectal cancer for mortality.

1

icon_c_breast.png

Female Breast Cancer  11.7%

2

icon_c_lung.png

Lung Cancer  11.4%

3

icon_c_colorectal.png

Colorectal Cancer  10.0%

4

icon_c_prostate.png

Prostate Cancer  7.3%

5

icon_c_stomach.png

Stomach Cancer 5.6%

Important Health Screening

icon_check_edited.png
important_graph.png

Analysis by Centre for Population Health Data, Statistics Canada

Data sources Canadian Cancer Registry death linked file (1992–2014) and life tables at Statistics Canada

icon_g_survival.png

Early detection can clearly have a huge benefit. A person whose cancer is found before it has spread to other parts of the body is more than four times as likely to survive five years than a person diagnosed with advanced disease. In patients with lung cancer, the difference is more than tenfold. Recent models suggest that shifting the stage of diagnosis from metastatic to localized cancers could potentially reduce five-year cancer-related mortality by up to 24 percent in people aged 50–79 years old.

icon_check_edited.png

Early cancer diagnosis

saves lives,

cuts treatment costs

icon_stage2.png
icon_diagnosis.png

Early cancer diagnosis

icon_stage.png
icon_cutcost.png

Cuts treatment costs

Strategies to improve early diagnosis can be readily built into health systems at a low cost. In turn, effective early diagnosis can help detect cancer in patients at an earlier stage, enabling treatment that is generally more effective, less complex, and less expensive. For example, studies in high-income countries have shown that treatment for cancer patients who have been diagnosed early are 2 to 4 times less expensive compared to treating people diagnosed with cancer at more advanced stages.

OUR SOLUTION

Important Health Screenings

Screening is a different strategy than early diagnosis

It is defined as the presumptive identification of unrecognized disease in an apparently healthy, asymptomatic population by means of tests, examinations or other procedures that can be applied rapidly and easily to the target population.
A screening program must include all the core components in the screening process from inviting the target population to accessing effective treatment for individuals diagnosed with disease.
illust.png

Breast Cancer CA15-3
Rapid Test Kits

Quickly diagnosing

tumor makers

(CA: Cancer Antigen)

breastCancer.png
icon_check_edited_edited_edited_edited.p

Test Procedure - Home Test

Directions for use 1 :

Using capillary fingertip blood

icon_check_edited_edited.png

Test Procedure - For Professional Use

Directions for use 2 :

Using serum/plasma/whole blood(venous blood)

icon_check_edited_edited_edited.png

Certificate

certification.png
In order to manufacture safe and high-quality products, we have secured GMP facilities and manufacture them with permission from the Korean FDA based on ISO 9001, ISO 13485, prepare all kinds of documentary evidence such as EO(Ethylene Oxide) gas or gamma-ray for sterilization, Certificate of Analysis, CE mark certification, FDA, ISO, etc. and sell them in Korea and abroad.
 

OUR TECHNOLOGY

icon_check_edited.png

Breast Cancer & CA(Cancer Antigen) 15-3

CA15-3 is one of the Food and Drug Administration (FDA)-approved tumor makers for monitoring breast cancer.

CA15-3 is a protein that is also produced in normal breast cells. In many breast cancer patients, the production of CA15-3 and CA 27.29 is increased. CA15-3 does not cause cancer, but is secreted from tumor cells and enters the bloodstream, thereby becoming useful as a tumor maker to track the course of cancer. CA15-3 is elevated in about 10% of women with early-stage localized breast cancer and about 70% of women with metastatic breast cancer. CA15-3 may be elevated in healthy individuals and may also be elevated in other cancers or other conditions such as colorectal cancer, lung cancer, cirrhosis, hepatitis and benign breast disease.

lab
lab1
about_bg
lab2
tech_bg
icon_check_edited.png

Lateral flow test diagnostics

Basically, it is a simple to use diagnostic device used to confirm the presence or absence of a target analyte, such as pathogens or biomarkers in humans or animals, or contaminants in water supplies, foodstuffs, or animal feeds. The most commonly known type of lateral flow rapid test strip is the pregnancy test.

LFAs typically contain a control line to confirm the test is working properly, along with one or more target or test lines. They are designed to incorporate intuitive user protocols and require minimal training to operate. They can be qualitative and read visually, or provide data when combined with reader technology.

leteral_flow_work.png

KEY FACTORS

Advantages of lateral flow assays

Fast Results

Time-to-results are produced in less than 5 min

Cost Effective

Highly affordable end use cost for commercialization

Field Ready

Portable and can be operated in resource limited areas

Easy to Use

Testing made simple. Intuitive design with minimal handling

 
main_bg_edited.jpg

Early diagnosis
Saves Lifes

CONTACT US

Get in Touch

Thanks for submitting!